Compare Mercadolibre Inc (MELI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Mercadolibre Inc trades at $1,879.74 (market cap $94.13B), while State Street SPDR S&P Biotech ETF trades at $153.76 (market cap $10.11B). The key difference: Mercadolibre Inc is far larger — about 9.3× State Street SPDR S&P Biotech ETF's market cap, and Mercadolibre Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MELI | XBI | |
|---|---|---|
Market Cap | $94.13B | $10.11B |
Volume | 273,781 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $2.36K | $169.55 |
52-Week Low | $1.55K | $104.99 |
Typical Hold Time | 117 Days | 38 Days |
Enterprise Value | $101.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,873.57, up 0.04% on the day, with a bullish technical signal from moving averages and strong support near $1,813. The company reported $28.89B revenue in 2025, though net income margin dipped to 6.91%, and recent earnings show mixed results with a beat in Q2 2026 but misses in prior quarters. Analyst consensus is strongly positive with a $2,170 price target, and cash flow from operations surged to $12.12B in 2025, underscoring robust financial health.
Outlook remains favorable due to dominant e-commerce and fintech positioning in Latin America, with revenue projected to hit $35.2B in 2026. Risks include profit margin pressures and macroeconomic volatility in key markets like Argentina. Institutional sentiment is bullish, with 73% of analysts rating it Buy, supporting potential upside near all-time highs.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
